Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Repligen Completes Expansion of U.S. Manufacturing Facility

Published: Thursday, November 07, 2013
Last Updated: Thursday, November 07, 2013
Bookmark and Share
Waltham boost doubles chromatography capacity.

Repligen Corporation has announced that it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met.

A dedicated production suite more than doubles capacity for the Company's OPUS® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers.

"This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen.

Herlihy continued, "The new cleanroom suite enables us to produce OPUS® columns under the highest quality standard demanded by biopharmaceutical manufacturers."

The facility expansion also triples warehouse space and includes dedicated purification and fermentation laboratories for optimization of existing manufacturing processes, new product development and applications support.

An additional 17,000 square feet is reserved for future expansion of the same facility, allowing the Company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Repligen Acquires Atoll
Acquisition expands Repligen’s pre-packed column chromatography portfolio into high throughput process development screening.
Tuesday, April 05, 2016
Repligen Completes Expansion of U.S. Facility
Includes manufacturing for ATF system.
Thursday, February 12, 2015
Michael A. Griffith Appointed to Repligen Board of Directors
Mr. Griffith has extensive leadership experience in the bioprocessing and biopharmaceutical industries, as well as significant commercial and investment banking expertise.
Thursday, April 12, 2012
Repligen Acquires Business of Novozymes Biopharma Sweden AB
Acquisition diversifies and expands Repligen’s product offering and customer base.
Tuesday, November 22, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!